Table 1: Baseline characteristics for 42 patients with advanced gastro-esophageal adenocarcinoma treated with DOX.
Number of patients |
42 |
Age, years Median range |
64 44-76 |
Sex Male Female |
36 (86%) 6 (14%) |
WHO performance status 0 1 |
24 (57%) 18 (43%) |
Primary tumour site Esophagus GEJ Stomach |
12 (28%) 23 (55%) 7 (17%) |
Status of primary tumour R0 resection R2 resection No surgery No patient had prior CT or RT |
5 (12%) 1 (2%) 36 (86%) |
Stage Locally advanced Metastatic |
3 (7%) 39 (93%) |
No. of organs involved 1 2 3 ≥ 4 |
2 (5%) 14 (36%) 14 (36%) 9 (23%) |
Increased Alkaline phosphatase (> 300 U/l) ALAT (> 40 U/l) Platelets (> 400 × 109 /l) ANC (> 7.5 × 109 /l) |
4 (10%) 6 (14%) 14 (33%) 22 (52%) |